Professor of Medicine, University Tex Houston
Oncology
Dr. Robert C. Bast Jr., MD
|
|
Give Review
Robert Bast practices Oncology. He graduated from Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He over the years received 2 awards: "Elected Member" and "Whos Who in Medicine and Healthcare". Robert Bast has written publications. He has 99 publications published with PubMed. The lastest publication is: 'Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.' He is registered with Medicare and accepts Medicare payments.
Publications
- Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.
- Downregulation of TRIM27 expression inhibits the proliferation of ovarian Cancer cells in vitro and in vivo.
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian Cancer detection at the point-of-care.
- Activating and propagating polyclonal gamma delta T cells with broad specificity for Malignancies.
- How will we recruit, train, and retain physicians and scientists to conduct translational Cancer research?
- Clinically Relevant microRNAs in Ovarian Cancer.
- DIRAS3 regulates the autophagosome initiation complex in dormant ovarian Cancer cells.
- Erratum to: Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast Jr RC. DIRAS3 regulates the autophagosome initiation complex in dorm...
- ARHI (DIRAS3) induces autophagy in ovarian Cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating th...
- Risk perception, worry, and test acceptance in average-risk women who undergo ovarian Cancer screening.
- A 2-stage ovarian Cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident Cancers and demonstrates high positive pr...
- The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial Carcinomas.
- CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer.
- Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies.
- Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.
- A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
- The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian Cancer cell migration through multiple mechanisms.
- Paclitaxel inhibits ovarian tumor growth by inducing epithelial Cancer cells to benign fibroblast-like cells.
- Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian Cancer cells through induction of apoptosis and downregulation of histon...
- Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer.
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian Cancer.
- Minireview: human ovarian Cancer: biology, current management, and paths to personalizing therapy.
- Dissecting "PI3Kness": The Complexity of Personalized Therapy for Ovarian Cancer.
- FOXO3a dependent mechanism of E1A-Induced chemosensitization.
- Src family kinases and paclitaxel sensitivity.
- The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells.
- Modulating microtubule stability enhances the cytotoxic response of Cancer cells to paclitaxel.
- Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, coloRectal, and o...
- Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage...
- More than a biomarker: CA125 may contribute to ovarian Cancer pathogenesis.
- Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3.
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithe...
- Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian Cancer cell lines and xenografts while inducing expression of imprinted tumor suppresso...
- Ovarian cancer biomarker performance in prostate, lung, coloRectal, and ovarian cancer screening trial specimens.
- A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian Cancer.
- A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies.
- Targeting aldehyde dehydrogenase Cancer stem cells in ovarian Cancer.
- Dasatinib induces autophagic cell death in human ovarian Cancer.
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian Cancer in patients with a pelvic mass.
- Personalizing therapy for ovarian Cancer: BRCAness and beyond.
- CA 125 and the detection of recurrent ovarian Cancer: a reasonably accurate biomarker for a difficult disease.
- Stanniocalcin 1 and Ovarian tumorigenesis.
- Serum biomarker panels for the discrimination of benign from Malignant cases in patients with an adnexal mass.
- ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins.
- Development of a multimarker assay for early detection of ovarian Cancer.
- Current state of biomarker development for clinical application in epithelial ovarian Cancer.
- Induction of papillary Carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
- Project Zero Delay: a process for accelerating the activation of Cancer clinical trials.
- MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian Carcinoma.
- A novel hTERT promoter-driven E1A therapeutic for ovarian Cancer.
- Urinary levels of Bcl-2 are elevated in ovarian Cancer patients.
- CA125/MUC16 is dispensable for mouse development and reproduction.
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian Cancer in patients with a pelvic mass.
- Tumor suppressor genes.
- Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast Cancer xenografts that overexpress HER2.
- The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian Cancer cells.
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic Cancers.
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenoCarcinoma of the uterus.
- Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian Cancers by loss of heterozygosity and promoter methylation.
- Opportunities and challenges in ovarian Cancer research, a perspective from the 11th Ovarian Cancer action/HHMT Forum, Lake Como, March 2007.
- The use of multiple novel tumor biomarkers for the detection of ovarian Carcinoma in patients with a pelvic mass.
- Combining multiple serum tumor markers improves detection of stage I epithelial ovarian Cancer.
- Clinical trial endpoints in ovarian Cancer: report of an FDA/ASCO/AACR Public Workshop.
- Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expressi...
- How do you distinguish a Malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.
- Urinary mesothelin provides greater sensitivity for early stage ovarian Cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
- The role of constitutively active signal transducer and activator of transcription 3 in Ovarian tumorigenesis and prognosis.
- Biomarkers and clinical trial design.
- The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and Ovarian tumorigenesis.
- Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
- Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian Cancer.
- 10th Biennial Helene Harris Memorial Trust meeting.
- Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian Cancer.
- Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian Cancer.
- Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast Cancers.
- Potential markers that complement expression of CA125 in epithelial ovarian Cancer.
- Prospective study using the risk of ovarian Cancer algorithm to screen for ovarian Cancer.
- Patterns of gene expression in different histotypes of epithelial ovarian Cancer correlate with those in normal fallopian tube, endometrium, and colon.
- Translational crossroads for biomarkers.
- A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian Cancer cells.
- Gene expression profiles predict early relapse in ovarian Cancer after platinum-paclitaxel chemotherapy.
- Genes affecting the Cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT ...
- Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian Cancer.
- HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
- Individualized care for patients with Cancer - a work in progress.
- Preoperative sensitivity and specificity for early-stage ovarian Cancer when combining Cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating fac...
- Expression of the tumor suppressor gene ARHI in epithelial ovarian Cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
- Three biomarkers identified from serum proteomic Analysis for the detection of early stage ovarian cancer.
- Biomarkers, surrogate end points, and the acceleration of drug development for Cancer prevention and treatment: an update prologue.
- Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian Cancer.
- Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition Analysis.
- Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian Cancer cells.
- A genetically defined model for human ovarian Cancer.
- Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
- Inhibition of Breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
- Early detection of ovarian Cancer: new technologies in pursuit of a disease that is neither common nor rare.
- Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast Cancer.
Schools
Harvard Medical School
Johns Hopkins Hospital
Peter B Brigham Hospital
Sidney Farber Cancer Institute
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- GEHA
- Health Alliance
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
Brigham and Women's Hospital -
Johns Hopkins University -
Harvard Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Similar Doctors
|
|
Dr. Shagufta N. Naqvi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cristina Rodriguez, MD |
|
|
Dr. Daniel J. Booser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvonne H. Sada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Cottingham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Escudier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon M. Giordano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. Lippman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Julie A. Ellerhorst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chung C. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajul Jain, MD |
|
|
Dr. Rammurti T. Kamble, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdul-Masih F P. Farha, MD |
|
|
Dr. Michael Andreeff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. An N. Hoang, MD |
|
|
Dr. Mindy Hsiong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karin Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Lin, MD |
|
|
Dr. Amir A. Rasheed, MD
This Doctor is OpenDoctor Recommended.
|